Sarepta Therapeutics, Inc. (SRPT) return on equity (ROE)

Return on equity · fiscal 2025
-62.5%

Sarepta Therapeutics, Inc. (SRPT) earned a return on equity of -62.5% in fiscal 2025 (the year ended December 31, 2025). That is 77.9 percentage points lower than the 15.4% of fiscal 2024. Figures as of 17 Nov 2026, 23:36 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-62.5%
Change on fiscal 2024
−77.9 pts
Highest on record
15.4%fiscal 2024
Lowest on record
-182.7%fiscal 2022
Fiscal years on record
162009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Sarepta Therapeutics, Inc. return on equity (ROE), in more detail

Across the 16 fiscal years on record (2009–2025), the highest was 15.4% in fiscal 2024 and the lowest -182.7% in fiscal 2022. The fiscal 2025 figure is higher than in 47% of the 15 earlier fiscal years on record, whose median is -62.4%.

History · 16 fiscal years

Return on equity by fiscal year

Sarepta Therapeutics, Inc. return on equity (ROE), year by year

Sarepta Therapeutics, Inc. (SRPT) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-62.5% 77.9 pts down
202415.4% 77.8 pts up
2023-62.4% 120.4 pts up
2022-182.7% 137.6 pts down
2021-45.1% 27.6 pts up
2020-72.7% 14.7 pts up
2019-87.4% 52.3 pts down
2018-35.1% 28.6 pts down
2017-6.4% 73.0 pts up
2016-79.4% 36.2 pts up
2015-115.6% 60.8 pts down
2014-54.8% 9.5 pts down
2013-45.3% 52.8 pts up
2012-98.1% 90.6 pts down
2011-7.5%—
2009-106.5%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on SRPT

Sarepta Therapeutics, Inc., figure by figure

Sarepta Therapeutics, Inc. (SRPT) overview: price, valuation and scorecard

Sarepta Therapeutics, Inc. return on equity (ROE): questions and answers

What is Sarepta Therapeutics, Inc.'s return on equity?

Sarepta Therapeutics, Inc. (SRPT) earned a return on equity of -62.5% in fiscal 2025 (the year ended December 31, 2025). That is 77.9 percentage points lower than the 15.4% of fiscal 2024.

Is Sarepta Therapeutics, Inc.'s return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 47% of the 15 earlier fiscal years on record, whose median is -62.4%.

What are the highest and lowest return on equity figures on record for Sarepta Therapeutics, Inc.?

Across the 16 fiscal years on record (2009–2025), the highest was 15.4% in fiscal 2024 and the lowest -182.7% in fiscal 2022.

How is Sarepta Therapeutics, Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Sarepta Therapeutics, Inc. (SRPT) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/SRPT/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.